| Date Filed | Type | Description |
| 09/29/2023 |
4
| Drutz David (Director) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Granted 26,100 options to buy
@ $2.5, valued at
$65.3k
|
|
| 09/29/2023 |
4
| Hodges Philip (Director) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Granted 26,100 options to buy
@ $2.5, valued at
$65.3k
|
|
| 09/29/2023 |
4
| Sohn Catherine A. (Director) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Granted 26,100 options to buy
@ $2.5, valued at
$65.3k
|
|
| 09/29/2023 |
4
| GILL JOHN (Director) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Granted 26,100 options to buy
@ $2.5, valued at
$65.3k
|
|
| 09/29/2023 |
4
| SAYARE MITCHEL (Director) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Granted 26,100 options to buy
@ $2.5, valued at
$65.3k
|
|
| 09/29/2023 |
4
| Jorkasky Diane (Director) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Granted 26,100 options to buy
@ $2.5, valued at
$65.3k
|
|
| 09/28/2023 |
8-K
| Quarterly results |
| 08/16/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 08/16/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/15/2023 |
4
| Drutz David (Director) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Bought 300 shares
@ $2.875, valued at
$862.5 |
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/02/2023 |
4
| Garg Vipin K (President and CEO) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Granted 126 shares
@ $2.81, valued at
$354.1 |
|
| 08/02/2023 |
4
| Eisenstadt Richard I (CFO) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Granted 1,825 shares
@ $2.81, valued at
$5.1k
|
|
| 08/02/2023 |
4
| Harris Matthew Scott (Chief Medical Officer) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Granted 691 shares
@ $2.81, valued at
$1.9k
|
|
| 08/02/2023 |
4
| Roberts M Scot (Chief Scientific Officer) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Granted 568 shares
@ $2.81, valued at
$1.6k
|
|
| 08/02/2023 |
4
| Jordt Raymond M (Chief Business Officer) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Granted 1,832 shares
@ $2.81, valued at
$5.1k
|
|
| 07/10/2023 |
SC 13G/A
| STATE STREET CORP reports a 1.6% stake in EXIT FILING ALTIMMUNE INC |
| 07/06/2023 |
4
| GILL JOHN (Director) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Sold 2,714 shares
@ $15, valued at
$40.7k
|
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 03/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/27/2023 |
4
| Sohn Catherine A. (Director) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Granted 47,000 options to buy
@ $4.19, valued at
$196.9k
|
|
| 03/27/2023 |
3
| Sohn Catherine A. (Director) has filed a Form 3 on Altimmune, Inc. |
| 03/27/2023 |
8-K
| Appointed a new director |
| 03/24/2023 |
4
| Eisenstadt Richard I (CFO) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Bought 10,000 shares
@ $4.314, valued at
$43.1k
|
|
| 03/23/2023 |
4
| Harris Matthew Scott (Chief Medical Officer) has filed a Form 4 on Altimmune, Inc.|
Txns:
| Bought 10,000 shares
@ $4.22, valued at
$42.2k
|
|
| 03/21/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 02/28/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 02/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 5.5% stake in Altimmune, Inc. |
| 02/14/2023 |
SC 13G/A
| Avidity Partners Management LP reports a 8.1% stake in Altimmune Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 5.3% stake in Altimmune, Inc. |
|